Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
Immunoglobulin light chain amyloidosis remains incurable despite recent therapeutic advances, and is particularly difficult to treat in patients with amyloid cardiomyopathy. Based on evidence of activity in multiple myeloma, we designed a pilot study of an oral regimen of lenalidomide in combination...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2013
|
| 在線閱讀: | https://doi.org/10.3324/haematol.2013.084574 https://haematologica.org/article/download/6811/39169 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|